News
Verona progresses PhII trial of COPD inhaler
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.